Attached files

file filename
EX-31.2 - EX-31.2 - TETRAPHASE PHARMACEUTICALS INCd847135dex312.htm
EX-31.1 - EX-31.1 - TETRAPHASE PHARMACEUTICALS INCd847135dex311.htm
EX-21.1 - EX-21.1 - TETRAPHASE PHARMACEUTICALS INCd847135dex211.htm
EX-23.1 - EX-23.1 - TETRAPHASE PHARMACEUTICALS INCd847135dex231.htm
EX-32.1 - EX-32.1 - TETRAPHASE PHARMACEUTICALS INCd847135dex321.htm
EX-10.27 - EX-10.27 - TETRAPHASE PHARMACEUTICALS INCd847135dex1027.htm
EX-10.26 - EX-10.26 - TETRAPHASE PHARMACEUTICALS INCd847135dex1026.htm
EXCEL - IDEA: XBRL DOCUMENT - TETRAPHASE PHARMACEUTICALS INCFinancial_Report.xls
10-K - FORM 10-K - TETRAPHASE PHARMACEUTICALS INCd847135d10k.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Tetraphase Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David Lubner, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge on the date hereof:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 6, 2015

 

/s/ David C. Lubner

David C. Lubner

Senior Vice President and Chief Financial Officer